Your browser is no longer supported. Please, upgrade your browser.
SRNE Sorrento Therapeutics, Inc. daily Stock Chart
SRNE [NASD]
Sorrento Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.61 Insider Own34.21% Shs Outstand216.96M Perf Week61.66%
Market Cap3.29B Forward P/E65.55 EPS next Y0.22 Insider Trans0.05% Shs Float200.97M Perf Month86.06%
Income-270.20M PEG- EPS next Q-0.16 Inst Own15.00% Short Float24.09% Perf Quarter454.62%
Sales35.50M P/S92.79 EPS this Y-14.80% Inst Trans5.82% Short Ratio1.09 Perf Half Y388.81%
Book/sh0.63 P/B22.89 EPS next Y126.50% ROA-49.40% Target Price25.00 Perf Year555.45%
Cash/sh- P/C- EPS next 5Y37.00% ROE-297.90% 52W Range1.39 - 14.55 Perf YTD326.63%
Dividend- P/FCF- EPS past 5Y-11.10% ROI-91.30% 52W High-0.89% Beta3.17
Dividend %- Quick Ratio0.60 Sales past 5Y52.40% Gross Margin68.10% 52W Low937.41% ATR1.18
Employees310 Current Ratio0.60 Sales Q/Q38.50% Oper. Margin- RSI (14)83.86 Volatility16.14% 12.07%
OptionableYes Debt/Eq1.21 EPS Q/Q22.60% Profit Margin- Rel Volume1.39 Prev Close13.61
ShortableYes LT Debt/Eq1.07 Earnings- Payout- Avg Volume44.50M Price14.42
Recom2.00 SMA2065.41% SMA50113.81% SMA200277.67% Volume62,006,795 Change5.95%
Jul-31-20Reiterated H.C. Wainwright Buy $24 → $30
May-26-20Initiated Dawson James Buy $24
Oct-07-19Initiated JMP Securities Mkt Outperform $21
Jun-28-18Initiated B. Riley FBR, Inc. Buy $14.25
Jan-16-18Reiterated H.C. Wainwright Buy $20 → $30
May-22-17Reiterated Rodman & Renshaw Buy $30 → $20
May-22-17Reiterated FBR & Co. Outperform $13 → $9
Oct-03-16Initiated ROTH Capital Buy
Apr-06-16Reiterated FBR Capital Outperform $21 → $16
Mar-16-16Reiterated FBR Capital Outperform $22 → $21
Dec-22-15Initiated FBR Capital Outperform $22
Dec-07-15Resumed Rodman & Renshaw Buy $45
Aug-03-15Resumed MLV & Co Buy $34
Jul-29-15Reiterated Brean Capital Buy $17 → $26
May-28-15Initiated Brean Capital Buy $17
Mar-17-15Reiterated H.C. Wainwright Buy $13 → $20
Oct-02-14Initiated H.C. Wainwright Buy $11
Jun-19-14Initiated MLV & Co Buy $9
Dec-03-13Initiated Aegis Capital Buy $40
Nov-21-13Initiated CRT Capital Buy $11
Aug-07-20 02:01PM  
12:30PM  
10:35AM  
06:16AM  
Aug-05-20 10:57AM  
07:13AM  
Aug-04-20 06:28PM  
12:20PM  
Aug-03-20 05:18PM  
Jul-31-20 05:52PM  
Jul-29-20 10:34AM  
08:01AM  
Jul-27-20 01:11PM  
11:40AM  
11:39AM  
11:30AM  
10:50AM  
10:16AM  
06:20AM  
Jul-26-20 09:45AM  
Jul-25-20 02:36PM  
Jul-24-20 08:44PM  
04:33PM  
03:46PM  
12:59PM  
11:10AM  
10:20AM  
09:00AM  
07:02AM  
06:46AM  
Jul-23-20 05:50PM  
04:50PM  
01:30PM  
11:40AM  
08:35AM  
Jul-22-20 08:05PM  
07:00PM  
06:12PM  
04:45PM  
02:28PM  
01:00PM  
11:10AM  
10:10AM  
Jul-21-20 11:15AM  
10:09AM  
10:05AM  
08:06AM  
06:20AM  
Jul-20-20 11:40PM  
07:25PM  
03:21PM  
11:50AM  
10:58AM  
10:04AM  
09:00AM  
08:43AM  
08:35AM  
07:30AM  
06:20AM  
Jul-18-20 06:52PM  
Jul-17-20 01:30PM  
12:30PM  
12:20PM  
11:43AM  
06:49AM  
Jul-16-20 05:45PM  
02:00PM  
01:33PM  
12:10PM  
11:30AM  
09:45AM  
Jul-15-20 08:30PM  
07:10PM  
03:30PM  
03:00PM  
Jul-14-20 06:20AM  
Jul-13-20 11:01PM  
01:35PM  
01:00PM  
09:31AM  
01:30AM  
Jul-10-20 11:33PM  
Jul-09-20 07:15PM  
07:12PM  
04:44PM  
04:20PM  
03:54PM  
06:20AM  
12:20AM  
Jul-08-20 09:03PM  
06:46PM  
05:50PM  
11:30AM  
11:15AM  
09:45AM  
09:12AM  
Jul-07-20 02:43PM  
01:15PM  
10:02AM  
Jul-06-20 08:19PM  
Sorrento Therapeutics, Inc., a clinical stage biopharma company, develops therapies for cancer, autoimmune, inflammatory, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches. It also offers Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. In addition, the company's clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases. Further, it develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. Additionally, the company engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. It has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; and Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection, as well as a research testing agreement with The University of Texas Medical Branch at Galveston for the preclinical testing of Sorrento's COVID-19 therapeutic product candidates. The company was founded in 2006 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Smith Robin LDirectorMar 05Buy2.2740,00090,89660,000Mar 05 01:58 PM